Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D

Kate Sasser, PhD, Chief Scientific Officer at Tempus, and Neil Bence, PhD, of Bristol Myers Squibb, discuss how AI and RWD are shaping the future of oncology drug development in this presentation from the AACR Annual Meeting 2026.

May 28, 2026
Life Sciences
AI
RWD
Video
Headshot of Kate SasserKate Sasser, PhDChief Scientific Officer, Tempus
Headshot of Neil BenceNeil Bence, PhDSenior Vice President, Protein Homeostasis Thematic Research Center, Bristol Myers Squibb

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Unable to determine image content.

Integrating multimodal real-world data at trial design: a framework for improving oncology trials

2026-10-06
Life Sciences
RWD
Clinical Trials
White abstract folded triangle shape, pointing right, on a black background.Video
A translucent glowing sphere beneath the words “laying the foundation for the future of precision medicine.”

Tempus Foundation Models

2026-10-01
Pan-Cancer
Foundation Model
AI
White abstract folded triangle shape, pointing right, on a black background.Video
Abstract rings of light on a pale gradient beneath the words “With Tempus, you can move faster.”

The Tempus Data Advantage

2026-09-30
Life Sciences
Pan-Cancer
RWD